Qing Li PeptideSemaglutide
Qing Li Peptide's purity-focus record is strongest in GHK-Cu, Tirzepatide, and Retatrutide, where recent clean identity/purity/fill results offset earlier purity misses and fill swings. Evidence is deep and current but dispersed: TB-500, Tesamorelin, and BPC-157 carry repeated purity, identity, or large fill failures, with spotty batch detail.
Domain records, Wayback captures and supplier profiles point away from the Hong Kong-facing history Qing Li presents. The report maps cloned storefronts, exposed staff records and a Pioneer Peptide fee pattern seen in buyer reports.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Qing Li Peptide rows.
Cancel anytime
About Qing Li Peptide test results from Finnrick
Qing Li Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 13 peptides and 327 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Qing Li Peptide peptides in this dataset are Melanotan II (7 tests) and Semaglutide (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.